Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity - IHU ICAN – Institut de Cardiométabolisme et Nutrition
Article Dans Une Revue Brain Communications Année : 2023

Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity

Nora Kramkimel
  • Fonction : Auteur
Yann Vano
  • Fonction : Auteur
Joe Elie Salem
  • Fonction : Auteur
Yves Allenbach
  • Fonction : Auteur
Thierry Maisonobe
  • Fonction : Auteur
Souad Assaad
  • Fonction : Auteur
Antoine Pegat
  • Fonction : Auteur

Résumé

Abstract While the spectrum of neurological immune checkpoint inhibitor-related adverse events is expanding, patients’ outcomes are not well documented. This study aimed to assess outcomes of neurological immune-related adverse events and to identify prognostic factors. All patients experiencing grade ≥2 neurological immune-related adverse events identified at two clinical networks (French Reference Center for Paraneoplastic Neurological Syndromes, Lyon; and OncoNeuroTox, Paris) over five years were included. Modified Rankin scores were assessed at onset, 6, 12, 18 months, and last visit. A multi-state Markov model was used to estimate the transition rates between minor disability (mRS <3), severe disability (mRS 3-5), and death (mRS 6), over the study period. The state-to-state transition rates were estimated using maximum likelihood and variables were introduced into the different transitions to study their effects. A total of 147 patients were included out of 205 patients with a suspicion of neurological immune-related adverse events. The median age was 65 years (range 20–87) and 87/147 patients (59.2%) were male. Neurological immune-related adverse events involved the peripheral nervous system in 87/147 patients (59.2%), the central nervous system in 51/147 (34.7%), and both systems in 9/147 (6.1%). Paraneoplastic-like syndromes were observed in 30/147 patients (20.4%). Cancers included lung cancers (36.1%), melanoma (30.6%), urological cancers (15.6%), and others (17.8%). Patients were treated with programmed cell death protein (ligan) 1 (PD(L)1) inhibitors (70.1%), CTLA4 inhibitors (3.4%) or both (25.9%). Severe disability was reported in 108/144 patients (75.0%) at onset and in 33/146 patients (22.6%) at last visit (median follow-up duration: 12 months, range 0.5–50); 48/147 (32.7%) patients died, from cancer progression (17/48, 35.4%), neurological toxicity (15/48, 31.2%), other causes (10/48, 20.8%) or unknown causes (6/48, 12.5%). The rate of transition from severe to minor disability independently increased with melanoma [compared to lung cancer, hazard ratio = 3.26, 95%CI (1.27; 8.41)] and myositis/neuromuscular junction disorders [hazard ratio = 8.26, 95%CI (2.90; 23.58)], and decreased with older age [hazard ratio = 0.68, 95%CI (0.47; 0.99)] and paraneoplastic-like syndromes [hazard ratio = 0.29, 95%CI (0.09; 0.98)]. In patients with neurological immune-related adverse events, myositis/neuromuscular junction disorders and melanoma increase the transition rate from severe to minor disability, while older age and paraneoplastic-like syndromes result in poorer neurological outcomes; future studies are needed to optimize the management of such patients.
Fichier principal
Vignette du fichier
fcad169.pdf (967.08 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
licence

Dates et versions

hal-04503909 , version 1 (23-09-2024)

Licence

Identifiants

Citer

Antonio Farina, Cristina Birzu, Mad-Hélénie Elsensohn, Alberto Picca, Sergio Muñiz-Castrillo, et al.. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Communications, 2023, 5 (3), ⟨10.1093/braincomms/fcad169⟩. ⟨hal-04503909⟩
20 Consultations
0 Téléchargements

Altmetric

Partager

More